Who are we missing? Reporting of ethnicity, race, and sex‐specific populations in clinical trials

Low enrollment in randomized clinical trials (RCTs) hinders cardiovascular medicine advances. This disproportionately affects Black, Hispanic and Latino, and female patients who have disproportionately higher rates of cardiovascular risk factors and worse outcomes. Prior studies evaluated individual diseases, limited populations, and older trials, and used prior National Institutes of Health race and ethnicity definitions. Therefore, our objective was to quantitatively evaluate Black, Hispanic and Latino, and female patients’ representativeness using US disease and risk factor prevalences across contemporary cardiovascular trials. We hypothesized that these populations would be underrepresented across trial categories.

American Heart Association

Rachel Kohn, Dorothy Sheu, Emma Britez Ferrante, Adina Lieberman, Medha R Maitra, Josiah Drakes, Alisa J Stephens-Shields, Alexis K Okoh, Alexander C Fanaroff, Alanna A Morris, Modele O Ogunniyi, Neal W Dickert, Scott D Halpern, Meghan B Lane-Fall